Exendin-4 Recombinant is a glucagon like peptide-1 receptor agonist. The native hormone is produced in the gut of Gila monster Heloderma suspectrum (a type of reptile found in the desert) that stimulates insulin production without causing threateningly low blood sugar, which can occur after using insulin and some anti-diabetes products. Recently, researchers used extracted saliva from gila monsters to create an unprecedented breakthrough in Diabetes Type 2 treatment. Unlike other products taken for type 2 diabetes, Exedin-4 has not been linked with weight gain and actually resulted in weight loss, according to the researchers. Exedin-4 enhances glucose-dependant insulin secretion, suppresses inappropriately elevated glucagon secretion and slows gastric emptying in vivo. It also promotes B-cell proliferation and neogenesis in vitro and in animal models. Exedin-4 stimulates an increase in acinar cAMP, without stimulating the release of amylase.

Exendin-4 Recombinant is a novel 39-amino acids peptide having a molecular mass of 4186.7 Dalton, which shares 53%, sequence homology with GLP-17-36 amide and interacts with the same membrane receptor.
The Exendin-4 is purified by proprietary chromatographic techniques.